Researchers at the Chinese University of Hong Kong have developed a simpler and more affordable liquid-biopsy blood test to detect cancer [1].
This advancement matters because it could significantly reduce the reliance on invasive tissue biopsies. By providing a less painful alternative, the technology aims to make early cancer detection more accessible and accurate for patients [1].
Professor Allen Chan leads the research team at the university [1]. The team is focusing on creating a diagnostic tool that is not only cheaper than current methods but also more precise in identifying the presence of cancer through a blood sample [2].
Traditional biopsies often require the surgical removal of tissue, which can be painful and carry risks of complications. The liquid-biopsy approach seeks to bypass these issues by analyzing biomarkers in the blood [1]. This shift toward non-invasive testing could encourage more frequent screening and earlier intervention, which are critical factors in improving patient survival rates [2].
Details regarding the development of this test were highlighted as part of the fourth installment of a six-part Health Matters wellness series [1]. The project represents a broader effort in Hong Kong to integrate advanced biotechnology into routine clinical practice [1].
While the team continues to refine the accuracy of the test, the primary goal remains the reduction of patient distress associated with traditional diagnostic procedures [2]. The research team is working to ensure the test remains cost-effective to prevent financial barriers to early detection [1].
“The technology aims to make early cancer detection more accessible and accurate.”
The transition from tissue-based biopsies to liquid biopsies represents a shift toward personalized, minimally invasive medicine. If this cheaper and more accurate test is widely adopted, it could lower the threshold for cancer screening, potentially catching malignancies at stages where they are more treatable and reducing the healthcare costs associated with invasive surgical diagnostics.
